Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

CzechiaBack to Czechia

Clinical trials in Olomouc – page 7

342 clinical trials in Olomouc, Czechia across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

CzechiaOur site in CzechiaKlinickeTesty.cz(opens in a new tab)
Olomouc at a glance
342
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

342 trials in Olomouc

Open in trial search

Hormone-dependent prostate cancer

Recruiting

Study on the Effects of Darolutamide and Drug Combination for Patients with Metastatic Hormone-Naïve Prostate Cancer

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Lupus nephritis

Recruiting

Study on the Effects and Safety of Ianalumab in Adults with Lupus Nephritis Who Completed Previous Treatment

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Emtricitabine
  • Sponsor:Novartis Pharma AG

Chronic lymphocytic leukaemia+1

Recruiting

Study on Venetoclax, Obinutuzumab, and Pirtobrutinib for Patients with Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:University Of Cologne

Still's disease+1

Recruiting

Study on the Effectiveness and Safety of Deucravacitinib for Children and Teens with Juvenile Psoriatic Arthritis

Investigational
Countries:CzechiaCzechia
  • Participants:0–17 years
  • Substances:Deucravacitinib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Clostridium difficile colitis+1

Recruiting

Study on Optimizing Antibiotic Treatment for Clostridioides Difficile Infection with Vancomycin Hydrochloride in Adult Patients

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Vancomycin Hydrochloride
  • Sponsor:Fakultni Nemocnice Bulovka

Crohn's disease

Recruiting

Study on the Effectiveness and Safety of Obefazimod for Patients with Moderate to Severe Crohn's Disease After Inadequate Response to Other Treatments

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Obefazimod
  • Sponsor:Abivax

Subarachnoid haemorrhage

Recruiting

Study on the Safety and Effectiveness of Parecoxib and Sodium Chloride for Patients Hospitalized with Spontaneous Subarachnoid Hemorrhage

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Parecoxib
  • Sponsor:Fakultni Nemocnice U Sv Anny V Brne

Small cell lung cancer extensive stage

Recruiting

Study Comparing BMS-986489 with Chemotherapy to Atezolizumab with Chemotherapy for First-Line Treatment in Patients with Extensive-Stage Small Cell Lung Cancer

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Hormone-refractory prostate cancer+1

Recruiting

Study of PF-06821497 and Enzalutamide for Men with Advanced Prostate Cancer Resistant to Hormone Therapy

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide
  • Sponsor:Pfizer Inc.

Acute myeloid leukaemia

Recruiting

Study on the Effectiveness of Gilteritinib and Drug Combination for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Amsacrine
  • Sponsor:Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.

Glomerulonephritis minimal lesion+1

Recruiting

Study on Frexalimab, SAR442970, and Rilzabrutinib for Patients Aged 16-75 with Focal Segmental Glomerulosclerosis or Minimal Change Disease

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Hormone receptor positive HER2 negative breast cancer

Recruiting

Study on Elacestrant and Everolimus for Patients with Advanced ER+/HER2- Breast Cancer Resistant to Endocrine Therapy and CDK4/6 Inhibitors

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Elacestrant
  • Sponsor:Medica Scientia Innovation Research S.L.

Other cities in Czechia

The busiest research cities in the country

All 159 cities in Czechia

Clinical research in Olomouc

What the registry says about research in the country

01 Oncology Research

Groundbreaking studies focusing on multiple cancer types, including metastatic prostate cancer, lung cancer, and colorectal cancer. Research emphasizes innovative treatment approaches and combination therapies.

  • Prostate Cancer Treatment Evaluation
  • Lung Cancer Therapy Development
  • Cervical Cancer Treatment Comparisons

These trials aim to improve survival rates and treatment effectiveness across various cancer types.

02 Cardiovascular and Metabolic Disorders

Studies investigating treatments for heart failure prevention, obesity management, and cardiovascular disease. Focus on innovative therapeutic approaches and combination treatments.

  • Heart Failure Prevention Studies
  • Obesity Treatment Research
  • Cardiovascular Risk Management

Research aims to reduce cardiovascular events and improve patient outcomes.

03 Immunology and Inflammatory Conditions

Clinical investigations targeting Crohn's disease, chronic rhinosinusitis, and other inflammatory conditions. Studies evaluate novel therapeutic approaches and treatment optimization.

  • Inflammatory Bowel Disease Therapy
  • Autoimmune Disease Treatment
  • Infection Management Studies

Research focuses on improving treatment responses and patient quality of life.

Back to CzechiaAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.